The Synthesis and Structure of {[Pim^{Pri,But}]ZnOH}(ClO₄): A Tris(imidazolyl)phosphine Zinc Hydroxide Complex and a Proposed Structural Model For Carbonic Anhydrase

Clare Kimblin,^a William E. Allen^b and Gerard Parkin*^a

^a Department of Chemistry, Columbia University, New York, New York 10027, USA

^b Department of Chemistry, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 USA

The zinc hydroxide complex { $[Pim^{Pri,But}]ZnOH$ }(CIO₄) is synthesized by the reaction of $[Pim^{Pri,But}]$ with $Zn(CIO_4)_2 \cdot 6H_2O$; { $[Pim^{Pri,But}]ZnOH$ }(CIO₄) is the first structurally characterized monomeric zinc hydroxide complex supported by imidazole functionalities and is therefore an excellent structural model for the active site of carbonic anhydrase.

Carbonic anhydrase (CA), a ubiquitous zinc enzyme found in both plants and animals, has the essential function of catalysing the equilibration of hydrogencarbonate with carbon dioxide and water [eqn. (1)].¹

$$CO_2 + H_2O \leftrightarrows HCO_3 - + H^+ \tag{1}$$

The active site of the enzyme is composed of a pseudotetrahedral zinc centre coordinated to the nitrogen donors of three histidine imidazole groups, with the remaining coordination site occupied by the catalytically active moiety, namely a hydroxide or water ligand, depending upon pH.² In order to provide insight in to the nature of the catalytic cycle, considerable effort has been directed toward the syntheses of complexes that model either, or both, the structure and function of the active site.^{3–13} Despite these numerous studies, however, only two four-coordinate zinc hydroxide complexes supported by nitrogen donor ligands, namely the tris(3-tert-butyl-5methylpyrazolyl)hydroborato complex [Tp^{But,Me}]ZnOH^{7a} and the triazacyclododecane derivative [(tacd)Zn-(OH)]+,13b,14 have been structurally characterized. The latter, however, is actually a hydrogen-bonded trimer in the solid state, i.e. $[(tacd)Zn(OH)]_3(ClO_4)_3 \cdot (HClO_4)$. Even though $[Tp^{But,Me}]$ -ZnOH and $[(tacd)Zn(OH)]^+$ do indeed resemble the active site of carbonic anhydrase in that both exhibit a common [ZnN₃O] coordination sphere, their structural similarity to the enzyme is limited by the fact that the nitrogen donors are not imidazolylbased ligands. In this paper, we describe the synthesis and structure of the first well-defined monomeric four-coordinate zinc hydroxide complex that is supported by imidazole functionalities.

Many tridentate, tripodal, imidazolyl-based ligands, *e.g.* tris(imidazolyl)phosphine, tris(imidazolyl)carbinol and tris-



Scheme 1

(imidazolyl)alkane derivatives, have been used previously to model the function of carbonic anhydrase.^{4–6} Such systems, however, have not yet afforded structurally characterized examples of four-coordinate zinc-hydroxide or zinc-aqua complexes. Nevertheless, it seemed reasonable to consider that an appropriately substituted tris(imidazolyl)derivative should allow for the isolation of a monomeric zinc hydroxide



Fig. 1 ORTEP drawing of the cation in { $[Pim^{Pri},Bu^t]ZnOH$ }(ClO₄). Selected bond lengths (Å) and angles (°): Zn–O 1.860(5), Zn–N(12) 2.086(5), Zn–N(22) 2.088(5), Zn–N(32) 2.073(6); O–Zn–N(12) 121.7(2), O–Zn–N(22) 118.9(3), O–Zn–N(32) 124.6(3), N(12)–Zn–N(22) 94.5(2), N(22)–Zn–N(32) 94.0(2), N(12)–Zn–N(32) 95.9(2)].



Fig. 2 ORTEP drawing of the cation in {[Pim^{Pri,But}]ZnI}I. Selected bond lengths (Å) and angles (°): Zn-I(1) 2.516(3), Zn-N(12) 2.091(15), Zn-N(22) 2.114(15), Zn-N(32) 2.076(14); I(1)-Zn-N(12) 120.5(4), I(1)-Zn-N(22) 121.6(4), I(1)-Zn-N(32) 119.4(3), N(12)-Zn-N(22) 95.8(6), N(22)-Zn-N(32) 96.2(5), N(12)-Zn-N(32) 97.7(6).

Table 1	Comparison	of the coordination	environments abou	it zinc in carbonic	anhydrase and	structural models
---------	------------	---------------------	-------------------	---------------------	---------------	-------------------

 - <u> </u>	${[Pim^{Pr^{i},Bu^{t}}]ZnOH}^{+a}$	[Tp ^{Bu^t,Me}]ZnOH ^b	$[(tacd)Zn(OH)]^{+c}$	CA I ^d	CA II ^e
 Zn–O/Å	1.860(5)	1.850(8)	1.944(5)	1.9	2.05
Zn–N/Å	2.073(6) - 2.088(5)	2.052(5)	2.004(9)-2.042(9)	1.9	2.10-2.12
OZn-N (°)	118.9(3)-124.6(3)	123.2(2)	102.5(3)-127.2(3)	98-125	111.1-113.6
N–Zn–N (°)	94.0(2)-95.9(2)	92.8(2)	104.3(4)-107.0(4)	98-117	99.2-115.3

^a This work. ^b Ref. 7(a). ^c Ref. 13(b). ^d Ref. 2(d). ^e Ref. 2(a).



Fig. 3 ORTEP drawing of the cation in $\{[Pim^{Pi}, Bu^{l}]Zn(ONO_{2})\}(NO_{3})$. Selected bond lengths (Å) and angles (°): Zn-O(11) 1.986(4), $Zn\cdots O(12)$ 2.518(8), Zn-N(12) 2.054(4), Zn-N(22) 2.074(3), Zn-N(32) 2.048(3), N(1)-O(11) 1.278(6), N(1)-O(12) 1.237(8), N(1)-O(13) 1.217(7); O(11)-Zn-N(12) 121.5(2), O(11)-Zn-N(22) 111.7(2), O(11)-Zn-N(32) 124.1(1), O(11)-N(1)-O(12) 115.8(5), O(11)-N(1)-O(13) 120.3(6), O(12)-N(1)-O(13) 123.9(5), N(12)-Zn-N(22) 93.1(1), N(22)-Zn-N(32) 94.6(1), N(12)-Zn-N(32) 104.2(2).

derivative. By analogy with the tris(pyrazolyl)hydroborato complex [Tp^{But,Me}]ZnOH, in which the bulky *tert*-butyl substituents sustain the monomeric nature of the ZnOH functionality, we have explored the use of the sterically demanding tris[2-(1-isopropyl-4-*tert*-butylimidazolyl)]phosphine ligand [Pim^{Pri,But}], recently described by Sorrell,¹⁵ for the synthesis of a monomeric tris(imidazolyl)phosphine zinc hydroxide complex.

Indeed, the bulky tris(imidazolyl)phosphine [PimPri,But] readily forms a variety of well defined four-coordinate cationic zinc complexes { $[Pim^{Pri,But}]ZnX$ } + (X = OH, NO₃, I), as illustrated in Scheme 1. Of most significance is the zinc hydroxide complex {[Pim^{Pri,But}]ZnOH}+, which may be isolated as the perchlorate salt from the reaction of [PimPri,But] with $Zn(ClO_4)_2 \cdot 6H_2O$. The molecular structure of { $[Pim^{Pri,But}]$ -ZnOH}(ClO₄) has been determined by X-ray diffraction,† thereby confirming the presence of a discrete monomeric terminal zinc hydroxide complex (Fig. 1). The monomeric nature of ${[Pim^{Pri,But}]ZnOH}^+$ contrasts with that of the trimeric hydrogen-bonded structure of $[(tacd)Zn(OH)]_3$ - $(ClO_4)_3$ (HClO_4), ^{13b} but closely resembles that of its neutral analogue [Tp^{But,Me}]ZnOH.^{7a} The coordination environments about zinc in these hydroxide complexes are compared, in Table 1, with the corresponding values for carbonic anhydrase. Evidently, both the Zn–O and Zn–N bond lengths in {[Pim^{Pri-} ^{,But}]ZnOH}+ are in reasonable accord with those observed in both CA I and CA II. However, the Zn-O bond length in {[Pim^{Pri,But}]ZnOH}+ is closer to that in CA I than CA II, whereas the Zn-N bond lengths are between those in CA I and CA II.

The zinc iodide and zinc nitrate complexes, {[PimPri.But]-ZnI and { $[Pim^{Pri,But}]Zn(ONO_2)$ }(NO_3), are also readily synthesized by the reactions of $[Pim^{Pri,But}]$ with ZnI_2 and $Zn(NO_3)_2 \cdot 6H_2O$, respectively. The zinc iodide cation $\{[Pim^{Pri,But}]ZnI\}^+$ may also be obtained by treatment of the hydroxide derivative {[Pim^{Pri,But}]ZnOH}+ with Me₃SiI, a reaction that bears some relevance to the observation that iodide is an inhibitor of carbonic anhydrase.16 Furthermore, the molecular structure of {[PimPri,But]ZnI]I (Fig. 2)† is similar to the coordination environment about zinc in the iodide inhibitor complex of human carbonic anhydrase I,17 although the Zn-I bond length in { [Pim^{Pri,But}]ZnI }+ [2.516(3) Å] is notably shorter than that observed in the enzyme iodide complex (2.7 Å).^{17,18} The structure of $\{[Pim^{Pri,But}]Zn(ONO_2)\}^+$ has also been determined by X-ray diffraction (Fig. 3),† revealing the presence of a unidentate nitrate ligand analogous to that in $[Tp^{But}]Zn(ONO_2).^{8,19}$

Acknowledgement is made to the NIH (Grant GM46502) for support of this research. G. P. is the recipient of a Camille and Henry Dreyfus Teacher–Scholar Award (1991–1996), and a Presidential Faculty Fellowship Award (1992–1997). We thank Professor Thomas Sorrell for an initial gift of [Pim^{Pri,But}] and for a preprint of ref. 15.

Received, 9th May 1995; Com. 5/02913I

Footnote

† *Crystal data*: {[Pim^{Pri,But}]ZnOH}(ClO₄)·(Et₂O)·(CHCl₃) monoclinic, *P*2₁/*c* (No. 14), *a* = 17.064(5) Å, *b* = 16.263(4) Å, *c* = 19.068(4) Å, β = 114.84(2)°, *V* = 4830(2) Å³, *Z* = 4, *R* = 0.0608, *R*_w = 0.0696. {[Pim^{Pri,But}]ZnI}I-4(CHCl₃) monoclinic, *P*2₁/*c* (No. 14), *a* = 16.119(4) Å, *b* = 19.385(4) Å, *c* = 18.096(3) Å, β = 90.32(2)°, *V* = 5654(2) Å³, *Z* = 4, *R* = 0.0834, *R*_w = 0.0965. {[Pim^{Pri,But}]Zn(ONO₂)}(NO₃)·(MeCN) triclinic, *P*1 (No. 2), *a* = 10.503(4) Å, *b* = 13.099(6) Å, *c* = 14.245(3) Å, *α* = 104.19(2)°, β = 105.39(2)°, *γ* = 91.76(3)°, *V* = 1935(1) Å³, *Z* = 2, *R* = 0.0481, *R*_w = 0.0571. Atomic coordinates, bond distances and angles, and thermal displacement parameters have been deposited at the Cambridge Crystallographic Data Centre. See Information for Authors, Issue No. 1.

References

- I. Bertini and C. Luchinat, in *Bioinorganic Chemistry*, ed. I. Bertini, H. B. Gray, S. J. Lippard and J. Valentine, University Science Books, Mill Valley, California, 1994, *Carbonic Anhydrase*, ed. F. Botre, G. Gros and B. T. Storey, VCH, New York, 1991; D. W. Christianson, *Adv. Protein Chem.*, 1991, 42, 281; D. N. Silverman and S. Lindskog, *Acc. Chem. Res.*, 1988, 21, 30; P. Wooley, *Nature*, 1975, 258, 677; *The Carbonic Anhydrases*, ed. S. J. Dodgson, R. E. Tashian, G. Gros and N. D. Carter, Plenum, New York, 1991; S. Lindskog, *Adv. Inorg. Biochem.*, 1982, 4, 115; J. E. Coleman, *Ann. N.Y. Acad. Sci.*, 1984, 429, 26–48; Y. Pocker and S. Sarkanen, *Adv. Enzymol.*, 1978, 47, 149; B. L. Vallee, in *Zinc Enzymes*, ed. T. G. Spiro, Wiley, New York, 1983.
- 2 (a) K. Håkansson, M. Carlsson, L. A. Svensson and A. Liljas, J. Mol. Biol., 1992, 227, 1192; (b) A. E. Eriksson, T. A. Jones and A. Liljas, Proteins: Struct. Funct. Gen., 1988, 4, 274; (c) S. K. Nair and D. W. Christianson, J. Am. Chem. Soc., 1991, 113, 9455; (d) K. K. Kannan, Photon Fact. Act. Rep. Jpn., 1990, 8, 94 (data are cited in ref, 17).

J. CHEM. SOC., CHEM. COMMUN., 1995

- 3 P. J. Wooley, J. Chem. Soc., Perkin Trans. 2, 1977, 318.
- 4 R. S. Brown, M. Zamkanei and J. L. Cocho, J. Am. Chem. Soc., 1984, 106, 5222; H. Slebocka-Tilk, J. L. Cocho, Z. Frakman and R. S. Brown, J. Am. Chem. Soc., 1984, 106, 2421; R. S. Brown, N. J. Curtis and J. Huguet, J. Am. Chem. Soc., 1981, 103, 6953; R. S. Brown, D. Salmon, N. J. Curtis and S. Kusuma, J. Am. Chem. Soc., 1982, 104, 3188; J.Huguet and R. S. Brown, J. Am. Chem. Soc., 1980, 102, 7571.
- 5 C. C. Tang, D. Davalian, P. Huang and R. Breslow, J. Am. Chem. Soc., 1978, 100, 3918; R. S. Brown and J. Huguet, Can. J. Chem., 1980, 58, 889.
- 6 R. Breslow, J. T. Hunt, R. Smiley and T. Tarnowski, J. Am. Chem. Soc., 1983, 105, 5337.
- 7 (a) R. Alsfasser, S. Trofimenko, A. Looney, G. Parkin and H. Vahrenkamp, *Inorg. Chem.*, 1991, 30, 4098; (b) A. Looney, G. Parkin, R. Alsfasser, M. Ruf and H. Vahrenkamp, *Angew. Chem.*, *Int. Ed. Engl.*, 1992, 31, 92.
- A. Looney, R. Han, K. McNeill and G. Parkin, J. Am. Chem. Soc., 1993, 115, 4690; R. Han, A. Looney, K. McNeill, G. Parkin, A. L. Rheingold and B. S. Haggerty, J. Inorg. Biochem., 1993, 49, 105.
- 9 M. Ruf, K. Weis and H. Vahrenkamp, J. Chem. Soc., Chem. Commun., 1994, 135; R. Alsfasser, M. Ruf, S. Trofimenko and H. Vahrenkamp, Chem. Ber., 1993, 126, 703.
- 10 R. Gregorzik, U. Hartmann and H. Vahrenkamp, *Chem. Ber.*, 1994, **127**, 2117; U. Hartmann, R. Gregorzik and H. Vahrenkamp, *Chem. Ber.*, 1994, **127**, 2123.
- 11 N. Kitajima, S. Hikichi, M. Tananka and Y. Moro-oka, J. Am. Chem. Soc., 1993, 115, 5496; S. Hikichi, M. Tanaka, Y. Moro-oka and N. Kitajima, J. Chem. Soc., Chem. Commun., 1992, 814.
- 12 I. Tabushi and Y. Kuroda, J. Am. Chem. Soc., 1984, 106, 4580.

- (a) X. Zhang, R. van Eldik, T. Koike and E. Kimura, *Inorg. Chem.*, 1993, **32**, 5749; (b) E. Kimura, T. Shiota, T. Koike, M. Shiro and M. Kodama, *J. Am. Chem. Soc.*, 1990, **112**, 5805; (c) E. Kimura, Y. Kurogi, M. Shionoya and M. Shiro, *Inorg. Chem.*, 1991, **30**, 4524; (d) T. Koike, E. Kimura, I. Nakamura, Y. Hashimoto and M. Shiro, *J. Am. Chem. Soc.*, 1992, **114**, 7338; (e) E. Kimura, *Prog. Inorg. Chem.*, 1994, **41**, 443.
- 14 Abbreviations: tris(1-pyrazolyl)hydroborato ligands are represented by the abbreviation $[Tp^{R,R'}]$, with the 3- and 5-alkyl substituents listed, respectively, as superscripts; tris(2-imidazolyl)phosphines are represented by the abbreviation $[Pim^{R,R'}]$, with the 1- and 4-alkyl substituents listed, respectively, as superscripts; tacd = 1,5,9-triazacyclododecane.
- 15 T. N. Sorrell, W. E. Allen and P. S. White, Inorg. Chem., 1995, 34, 952.
- 16 Y. Pocker and T. L. Deits, J. Am. Chem. Soc., 1982, 104, 2424; P. L. Whitney and H. Brandt, J. Biol. Chem., 1976, 251, 3862; I. Bertini and C. Luchinat, Acc. Chem. Res., 1983, 16, 272.
- 17 V. Kumar, K. K. Kannan and P. Sathyamurthi, Acta Crystallogr., Sect. D, 1994, 50, 731.
- 18 The molecular structure of a related chloride complex {[tris(4,5-diisopropylimidazol-2-yl)phosphine]ZnCl}+ has also been determined. See: R. J. Read and M. N. G. James, J. Am. Chem. Soc., 1981, 103, 6947.
- 19 Even though nitrate is also an inhibitor of carbonic anhydrase, the structure of the nitrate complex of human carbonic anhydrase II indicates that the interaction of the nitrate ligand with the zinc centre is weak (with a Zn–O distance of 2.8 Å), and that the coordinated water molecule is not displaced. See: S. M. Mangani and K. Håkansson, *Eur. J. Biochem.*, 1992, **210**, 867.